Role of beta-adrenergic receptor blocking agents in hypertensive diseases: personal thoughts as the controversy persists [0.03%]
β受体阻滞剂在高血压疾病中的作用：争议持续存在之时的个人观点
Edward D Frohlich
Edward D Frohlich
The long history of the beta-adrenergic receptor blockers for the treatment of hypertension is fraught with many controversies. The first compound had severe untoward effects preventing their use until propranolol was introduced. It was fou...
Infections as a stimulus for coronary occlusion, obstruction, or acute coronary syndromes [0.03%]
感染与冠状动脉闭塞、阻塞或急性冠脉综合征的发病刺激因素的关系
Erkki Pesonen,Milad El-Segaier,Kenneth Persson et al.
Erkki Pesonen et al.
Background: Atherosclerosis is considered to be an inflammatory disease. Infections are a significant cause of inflammation. Acute infections might precipitate acute coronary syndromes (ACS) whereas chronic infections mig...
Regional functions of the left ventricle in patients with coronary slow flow and the effects of nebivolol [0.03%]
冠状动脉慢血流患者左心室节段收缩功能不全及奈比洛治疗对其影响
Yilmaz Gunes,Mustafa Tuncer,Unal Guntekin et al.
Yilmaz Gunes et al.
Background: Microvascular and endothelial dysfunction have been implicated for coronary slow flow (CSF). Nebivolol, besides its beta-receptor blocking activity, causes an endothelium-dependent vasodilatation through incre...
Controlled Clinical Trial
Therapeutic advances in cardiovascular disease. 2009 Dec;3(6):441-6. DOI:10.1177/1753944709345926 2009
Joachim Fauler
Joachim Fauler
Coronary heart disease is the leading cause of death in the Western world. Antithrombotic therapy is the cornerstone of its successful treatment. Clinical trials have demonstrated that antithrombotic therapy reduces the risk for recurrent m...
Gwilym M Morris,Mark R Boyett
Gwilym M Morris
Bradyarrhythmias are common and may be caused by sinus node dysfunction or conduction block. Many of these conditions can be treated by the implantation of electronic cardiac pacemakers that reduce mortality and morbidity in carefully selec...
EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics [0.03%]
EFFORT-D研究：依那普利叶酸片强化降压治疗在心衰患者中的有效性和安全性：研究设计和基线特征中文标题：EFFORT-D研究：依那普利叶酸片强化降压治疗在老年收缩期心力衰竭患者中降低心血管事件的疗效和安全性：研究设计及受试者特点
Amira Hassanein,Akshay Desai,Anil Verma et al.
Amira Hassanein et al.
Background: Both diastolic dysfunction and increased vascular stiffness represent important measures of target-organ damage in hypertension. Whether intensive blood pressure (BP) control can further improve these measures...
Randomized Controlled Trial
Therapeutic advances in cardiovascular disease. 2009 Dec;3(6):429-39. DOI:10.1177/1753944709341301 2009
Only systolic hypertension? [0.03%]
仅收缩期高血压吗？
Carlos Escobar,Rocio Echarri,Vivencio Barrios
Carlos Escobar